Inclusion:

1) Studies on DAO or HNMT in histamine degradation.

2) Studies examining genetic variants linked to DAO deficiency or HIT are limited.

3) Biomarkers or diagnostic tests for DAO activity.

4) Clinical interventions include DAO supplementation and low-histamine diets.

Exclusion:

Animal or in vitro studies without human validation, case reports with <5 participants, studies lacking objective biochemical or clinical endpoints, and non-peer-reviewed sources [2] [3] .

A total of 146 records were identified across PubMed, Scopus, and Web of Science. After removing 12 duplicates, 134 unique records remained for screening. During abstract review, 82 articles were excluded due to irrelevance to human DAO activity or HIT, non-English language, or lack of clinical data. Of the 52 full-text articles assessed, 18 were excluded for reasons including insufficient sample size (<5 participants), absence of biochemical or clinical endpoints, or non-peer-reviewed status. Ultimately, 34 studies met the inclusion criteria and were included in the qualitative synthesis [2] [3] [5] .

Study characteristics, populations, interventions, biomarkers, and outcomes were extracted. Due to heterogeneity, a narrative synthesis was applied [2] [3] .

Randomized controlled trials (RCTs) were assessed using CONSORT 2010; observational studies used STROBE [2] [3] .

AOC1 SNPs (rs10156191, rs2052129, rs1049742) were associated with lower serum DAO and symptom susceptibility [5] - [8] . Reduced DAO was also observed in celiac disease, Crohn’s disease, and other enteropathies [5] [7] .

DAO’s physiological expression is highest in the small intestinal mucosa, kidneys, and placenta, tissues characterized by rapid turnover and high exposure to biogenic amines. Studies utilizing immunohistochemistry have confirmed marked reductions in mucosal DAO in individuals with celiac disease, Crohn’s disease, and other inflammatory enteropathies [3] [6] . This local loss of DAO-producing enterocytes further supports the enzyme’s role as a frontline barrier against dietary histamine absorption.

Intestinal inflammation and dysbiosis impair DAO activity. Histamine-producing bacteria include Morganella morganii, Klebsiella pneumoniae, and Lactobacillus reuteri [7] . Probiotics like Bifidobacterium longum and Lactobacillus plantarum may enhance DAO indirectly [7] [12] .

Conversely, certain probiotic species, such as Bifidobacterium longum and Lactobacillus plantarum, have been associated with histamine metabolism and mucosal healing, and may indirectly enhance DAO function. However, current evidence is largely observational, and direct mechanistic effects on DAO activity have not been conclusively demonstrated [2] [12] . Restoration of microbial diversity following probiotic supplementation has correlated with improved symptom tolerance in small pilot trials, underscoring the intricate cross-talk between the gut microbiome and histamine metabolism [12] .

Copper, vitamin B6, and zinc deficiencies reduce DAO activity [8] . NSAIDs, antidepressants, antihypertensives, and some antibiotics inhibit DAO [8] (as shown in Table 1 ).

A broad range of medications inhibit DAO activity, either directly by competitive binding or indirectly through alterations in intestinal permeability. Common culprits include nonsteroidal anti-inflammatory drugs (NSAIDs), tricyclic antidepressants, antihypertensives, and some antibiotics [1] [2] . Chronic use of these medications can lower DAO levels, predisposing individuals to histamine intolerance even in the absence of genetic or dietary risk factors. Awareness of these pharmacologic interactions is therefore critical in patient management.

Across studies, patients with DAO deficiency exhibited highly variable symptom profiles encompassing gastrointestinal, dermatologic, neurologic, and cardiovascular domains. Gastrointestinal manifestations—particularly bloating, abdominal pain, and diarrhea—were the most frequently reported, followed by dermatologic symptoms such as flushing, urticaria, and pruritus [2] [5] . Neurologic symptoms, including headache, dizziness, and fatigue, were observed in up to 40% of participants in some cohorts [5] [9] .

The overlapping nature of these manifestations contributes to frequent misdiagnosis. Histamine intolerance is often mistaken for food allergy, mast cell activation syndrome (MCAS), or irritable bowel syndrome (IBS). However, unlike allergic responses, HIT is non-immunologic and primarily enzymatic. A subset of migraine sufferers, for example, has been shown to exhibit low serum DAO levels, and symptom relief following DAO supplementation provides indirect evidence for causality [9] [10] .

Symptoms include gastrointestinal (bloating, pain, diarrhea), dermatologic (flushing, urticaria), and neurologic (headache, dizziness) domains [1] - [3] [4] . Misdiagnosis is common [1] [3] .

Serum DAO activity (<3 - 10 U/mL) is widely used, complemented by plasma histamine or urinary 1-methylhistamine [4] [14] . Elimination-rechallenge diets confirm the diagnosis [1] [3] [5] .

In clinical practice, elimination-rechallenge diets remain the most reliable diagnostic approach. Patients typically follow a low-histamine diet for 2 - 4 weeks, after which histamine-containing foods are systematically reintroduced under observation. Symptom improvement during restriction and relapse upon reintroduction support a diagnosis of HIT [2] [4] . While not standardized, combining dietary response with serum DAO activity measurement enhances diagnostic confidence.

Evidence for DAO supplementation has grown over the past decade, with multiple controlled studies reporting symptomatic improvement in patients with confirmed or suspected DAO deficiency [9] - [11] (as shown in Table 2 ). Oral DAO formulations, typically derived from porcine kidney extracts, are designed to enhance histamine degradation in the intestinal lumen prior to absorption. Randomized controlled trials have demonstrated reductions in headache frequency, gastrointestinal distress, and skin symptoms among individuals receiving 4.2 mg DAO twice daily compared to placebo [9] [10] .

Abbreviations: DAO, diamine oxidase; IBD, inflammatory bowel disease; SIBO, small intestinal bacterial overgrowth; HNMT, histamine-N-methyltransferase.

In addition to enzyme therapy, low-histamine diets remain the cornerstone of management. These diets eliminate high-histamine foods such as aged cheese, cured meats, fermented vegetables, and alcoholic beverages for a limited period before guided reintroduction [2] [4] . When combined with enzyme supplementation, patients report more consistent symptom control and an improved quality of life.

Adjunctive interventions have also emerged. Probiotic supplementation using strains such as Bifidobacterium infantis and Lactobacillus plantarum has been shown to modulate gut microbiota composition and reduce histamine production [2] [12] . Likewise, repletion of vitamin B6 and copper may potentiate DAO activity in deficient individuals. Preliminary findings from small pilot studies suggest that a multimodal approach—combining a low-histamine diet, DAO supplementation, and cofactor replacement—provides the greatest therapeutic benefit [2] [9] [12] .

Abbreviations: DAO, diamine oxidase; HIT, histamine intolerance; BID, twice daily. Notes: Interventions were administered orally. Outcome measures included symptom frequency, severity, and biochemical markers where applicable.

DAO deficiency is multifactorial, linking gastrointestinal, metabolic, and systemic processes. Symptom variability depends on genetics, mucosal health, microbiome, nutrition, and pharmacologic exposure [1] - [15] .

The interplay between genetic predisposition and environmental stressors underscores the complexity of DAO deficiency. Individuals with certain AOC1 polymorphisms may have reduced baseline enzyme activity but remain asymptomatic until additional stressors—such as infection, chronic inflammation, or pharmacologic inhibition—further lower DAO capacity [6] - [8] . This threshold model helps explain why HIT symptoms often emerge later in life or following prolonged illness or medication use. Similarly, micronutrient deficiencies, particularly in copper and vitamin B6, may exacerbate the functional deficit in enzyme activity [2] [12] . These relationships highlight the need for clinicians to adopt a systems-based approach that assesses not just symptoms but also the biochemical, nutritional, and environmental context of the patient. While DAO plays a central role in extracellular histamine degradation, histamine-N-methyltransferase (HNMT) functions intracellularly, primarily in the liver and central nervous system. HNMT-mediated methylation of histamine is particularly relevant for neurologic symptoms such as headache, dizziness, and fatigue, which may persist even when DAO activity is normal. Integrating consideration of both DAO and HNMT provides a more complete understanding of histamine dysregulation and may help explain the heterogeneity of clinical manifestations in HIT.

The growing clinical recognition of HIT necessitates diagnostic precision and multidisciplinary collaboration. Currently, the lack of standardized laboratory thresholds for serum DAO activity complicates diagnosis. Reported cut-offs range widely, from 3 to 10 U/mL, and assay variability reduces comparability across studies [7] [14] . In clinical practice, until validated thresholds are established, practitioners should place greater weight on elimination-rechallenge dietary trials, using symptom improvement during restriction and relapse upon reintroduction to guide diagnosis and management [7] [14] . Developing international reference standards for DAO measurement, as well as integrating additional markers such as urinary 1-methylhistamine, could substantially improve diagnostic reliability. From a practical standpoint, the combination of symptom-based assessment, elimination-rechallenge dietary trials, and serum DAO testing remains the most effective diagnostic strategy available [2] [4] .

Therapeutically, evidence supports the efficacy of oral DAO supplementation, particularly when combined with a low-histamine diet [9] - [11] . Randomized controlled trials have demonstrated symptom reduction across gastrointestinal and neurological domains, including migraine, when DAO is administered with meals. However, interindividual variability in response underscores the need for personalized treatment algorithms. Patients with genetic polymorphisms may require higher or sustained doses, while those with nutrient deficiencies or dysbiosis may benefit more from cofactor correction and probiotic therapy. Furthermore, awareness of drug-induced DAO inhibition is essential; reviewing and modifying medication regimens can significantly improve symptom outcomes [1] [2] [12] .

Future research should prioritize standardization, stratification, and integration. Standardization involves harmonizing DAO assays, histamine quantification methods, and dietary histamine databases. The absence of uniform measurement protocols remains one of the principal barriers to comparing outcomes across clinical studies [7] [14] . Stratification refers to segmenting patient populations according to genotype, microbiome profile, and nutrient status—factors that significantly influence therapeutic response. Such stratification could transform DAO research from descriptive observation into predictive medicine.

Integration calls for multi-omics approaches that combine genomics, metabolomics, and metagenomics to capture the complexity of histamine regulation. These technologies can help identify molecular endotypes of DAO deficiency, distinguishing those driven by enzyme dysfunction from those dominated by microbiome imbalance or immune dysregulation [3] [8] [12] . The intersection of these datasets could yield biomarkers that not only diagnose DAO deficiency but also predict which interventions—enzyme therapy, diet, or microbial modulation—will be most effective.

From a public-health standpoint, DAO deficiency illustrates the broader challenge of integrating nutritional biochemistry into mainstream medicine. The global prevalence of histamine intolerance is difficult to estimate, but increasing recognition in clinical and consumer health literature suggests substantial underdiagnosis [2] [15] . The societal cost of misdiagnosis—manifesting as repeated medical consultations, unnecessary testing, and chronic medication use—highlights the urgency of raising awareness among healthcare professionals. Public-health frameworks could incorporate screening for HIT in patients with refractory gastrointestinal or allergy-like symptoms, particularly among high-risk groups such as women with IBS, chronic migraine sufferers, or those on long-term polypharmacy [5] [7] . Developing clinical guidelines for HIT and DAO deficiency should become a priority for gastroenterology and nutrition societies. Such guidelines would standardize assessment, dietary education, and supplement quality assurance, reducing variability in patient outcomes. Moreover, ensuring regulatory oversight of DAO supplement manufacturing would enhance product consistency and safety. Educational initiatives targeting primary care clinicians could bridge the gap between patient-reported experiences and evidence-based practice.

This systematic review has several limitations that should be acknowledged. The primary constraint lies in the heterogeneity of study designs, populations, and outcome measures, which limited the feasibility of quantitative synthesis. Many included studies were small in scale, lacked control groups, or relied on subjective symptom assessments rather than standardized biochemical endpoints [2] [4] [7] . Variations in DAO assay methodologies and differing diagnostic thresholds further complicated data comparison across studies. Publication bias cannot be excluded, as positive findings on DAO supplementation and low-histamine diets are more likely to be reported than neutral or negative results [9] - [11] . Despite these limitations, the convergence of evidence across diverse study types supports the biological and clinical relevance of DAO deficiency. Future large-scale, randomized controlled trials using standardized diagnostic criteria and validated biomarkers are essential to strengthen the evidence base and guide the development of clinical guidelines.